Case Activity (76642)

1. Order | Filed: July 09, 2026 | Entered: July 09, 2026 ULTRAGENYX PHARMACEUTICAL INC. et al v. NAVINTA LLC et al

   Patent - Abbreviated New Drug Application(ANDA) | New Jersey

   Order on Motion to Seal

   ORDER granting Esjay Defendants' 151 Motion to Seal. Signed by Magistrate Judge Michael A. Hammer on 7/9/2026. (sks)

2. Order | Filed: July 09, 2026 | Entered: July 09, 2026 IN RE METFORMIN MARKETING AND SALES PRACTICES LITIGATION

   Other Fraud | New Jersey

   Order

   TEXT ORDER: The Court has reviewed the parties' July 8, 2026 joint status report [D.E. 674]. The tone and mutual finger-pointing in the joint status report make clear that there has been a fundamental breakdown in the meet-and-confer process. It is also evident from the fact that no counsel for the Third-Party Payor Plaintiffs appeared for the meet-and-confer. However, the Court knows all counsel in this matter to be highly experienced, capable, and diligent attorneys. Accordingly, the Court will afford the parties one, final opportunity to reach agreement through the meet-and-confer process. All affected parties shall immediately renew their meet-and-confer efforts to agree on either: (1) production dates for each of the discovery items still outstanding (i.e., (i) Amneal's production of responsive documents from the approximately 400,000 documents universe that its filter excluded; (ii) MSPRC's long overdue data production; and (iii) the medical and pharmacy-claims data that the TPPs owe), or (2) a single deadline for substantial completion of written discovery. The July 15th conference will proceed as scheduled. If counsel do not report that they have reached agreement, the Court will set its own deadline at that conference, and there will be no further extensions allowed. So Ordered by Magistrate Judge Michael A. Hammer on 7/9/2026. (Hammer, Michael)

3. 76640 additional result(s)